Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Mara Serena Serafini; Carolina Reduzzi; Rubina Qamar; null et al; Aurora Complex General Surgical Oncology Faculty

doi:10.1158/1538-7445.Am2024-3707

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Mara Serena Serafini, Carolina Reduzzi, Rubina Qamar, et al, Aurora Complex General Surgical Oncology Faculty

Complex General Surgical Oncology Faculty at Aurora

Advocate Health - Midwest

Research output: Contribution to journal › Meeting abstract

Original language	American English
Pages (from-to)	3707-3707
Number of pages	1
Journal	Cancer Research
Volume	84
Issue number	6_Supplement
DOIs	https://doi.org/10.1158/1538-7445.Am2024-3707
Status	Published - Mar 22 2024

Keywords

Circulating tumor cells
CTC
metastatic breast cancer
PACE study

Access to Document

10.1158/1538-7445.Am2024-3707License: Unspecified

https://libkey.io/libraries/1712/10.1158/1538-7445.AM2024-3707

Cite this

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study. / Serafini, Mara Serena; Reduzzi, Carolina; Qamar, Rubina et al.
In: Cancer Research, Vol. 84, No. 6_Supplement, 22.03.2024, p. 3707-3707.

Research output: Contribution to journal › Meeting abstract

Serafini, MS, Reduzzi, C, Qamar, R, et al & Complex General Surgical Oncology Faculty, A 2024, 'Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study', Cancer Research, vol. 84, no. 6_Supplement, pp. 3707-3707. https://doi.org/10.1158/1538-7445.Am2024-3707

@article{fb57de7f87f34e1581cb509cf043f429,

title = "Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study",

keywords = "Circulating tumor cells, CTC, metastatic breast cancer, PACE study",

author = "Serafini, {Mara Serena} and Carolina Reduzzi and Rubina Qamar and {et al} and {Complex General Surgical Oncology Faculty}, Aurora",

note = "Serafini MS, Reduzzi C, Gerratana L, et al. Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study. Cancer Research. 2024;84(6_Supplement):3707-3707. doi:10.1158/1538-7445.Am2024-3707",

year = "2024",

month = mar,

day = "22",

doi = "10.1158/1538-7445.Am2024-3707",

language = "American English",

volume = "84",

pages = "3707--3707",

journal = "Cancer Research",

number = "6_Supplement",

}

TY - JOUR

T1 - Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

AU - Serafini, Mara Serena

AU - Reduzzi, Carolina

AU - Qamar, Rubina

AU - et al, null

AU - Complex General Surgical Oncology Faculty, Aurora

N1 - Serafini MS, Reduzzi C, Gerratana L, et al. Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study. Cancer Research. 2024;84(6_Supplement):3707-3707. doi:10.1158/1538-7445.Am2024-3707

PY - 2024/3/22

Y1 - 2024/3/22

KW - Circulating tumor cells

KW - CTC

KW - metastatic breast cancer

KW - PACE study

UR - https://institutionalrepository.aah.org/auroragme/472

UR - https://libkey.io/libraries/1712/10.1158/1538-7445.AM2024-3707

U2 - 10.1158/1538-7445.Am2024-3707

DO - 10.1158/1538-7445.Am2024-3707

M3 - Meeting abstract

VL - 84

SP - 3707

EP - 3707

JO - Cancer Research

JF - Cancer Research

IS - 6_Supplement

ER -

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Keywords

Access to Document

Other files and links

Cite this